Entyvio 300 MG vial 1S
Ended Awarded
- Contract number
- SPE2DR26FBTBB
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $48,807
Award facts
- Contract value 100% obligated
- $48,806.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for ENTYVIO 300 mg vials valued at $48.8K with a completion date of November 26, 2025. This delivery order was awarded on October 29, 2025, under a firm fixed-price contract type with no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its established relationships and small business status to distribute comprehensive pharmaceutical products and medical consumables to the Department of Defense.
This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499.9 million through December 31, 2036, structured with a 30-month base period and three 30-month option periods. This framework positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to supply an extensive portfolio of branded and generic prescription drugs, biologics, over-the-counter medications, and specialized medical consumables to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FBTBB?
SPE2DR26FBTBB was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DR26FBTBB worth?
The government has obligated $48,807 on SPE2DR26FBTBB.
Is contract SPE2DR26FBTBB an order under another contract?
Yes. SPE2DR26FBTBB is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTBB competed?
The extent of competition for SPE2DR26FBTBB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award